Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial

Stephen E. Gitelman, Peter A. Gottlieb, Mark R. Rigby, Eric I. Felner, Steven M. Willi, Lynda K. Fisher, Antoinette Moran, Michael Gottschalk, Wayne V. Moore, Ashley Pinckney, Lynette Keyes-Elstein, Sudeepta Aggarwal, Deborah Phippard, Peter H. Sayre, Linna Ding, Jeffrey A. Bluestone, Mario R. Ehlers

Research output: Contribution to journalArticlepeer-review

88 Scopus citations


Background: Type 1 diabetes results from T-cell-mediated destruction of β cells. Findings from preclinical studies and pilot clinical trials suggest that antithymocyte globulin (ATG) might be effective for reducing this autoimmune response. We assessed the safety and efficacy of rabbit ATG in preserving islet function in participants with recent-onset type 1 diabetes, and report here our 12-month results. Methods: For this phase 2, randomised, placebo-controlled, clinical trial, we enrolled patients with recent-onset type 1 diabetes, aged 12-35 years, and with a peak C-peptide of 0·;4 nM or greater on mixed meal tolerance test from 11 sites in the USA. We used a computer generated randomisation sequence to randomly assign patients (2:1, with permuted-blocks of size three or six and stratified by study site) to receive either 6·;5 mg/kg ATG or placebo over a course of four days. All participants were masked and initially managed by an unmasked drug management team, which managed all aspects of the study until month 3. Thereafter, to maintain masking for diabetes management throughout the remainder of the study, participants received diabetes management from an independent, masked study physician and nurse educator. The primary endpoint was the baseline-adjusted change in 2-h area under the curve C-peptide response to mixed meal tolerance test from baseline to 12 months. Analyses were by intention to treat. This is a planned interim analysis of an on-going trial that will run for 24 months of follow-up. This study is registered with, number NCT00515099. Findings: Between Sept 10, 2007, and June 1, 2011, we screened 154 individuals, randomly allocating 38 to ATG and 20 to placebo. We recorded no between-group difference in the primary endpoint: participants in the ATG group had a mean change in C-peptide area under the curve of -0·;195 pmol/mL (95% CI -0·;292 to -0·;098) and those in the placebo group had a mean change of -0·;239 pmol/mL (-0·;361 to -0·;118) in the placebo group (p=0·;591). All except one participant in the ATG group had both cytokine release syndrome and serum sickness, which was associated with a transient rise in interleukin-6 and acute-phase proteins. Acute T cell depletion occurred in the ATG group, with slow reconstitution over 12 months. However, effector memory T cells were not depleted, and the ratio of regulatory to effector memory T cells declined in the first 6 months and stabilised thereafter. ATG-treated patients had 159 grade 3-4 adverse events, many associated with T-cell depletion, compared with 13 in the placebo group, but we detected no between-group difference in incidence of infectious diseases. Interpretation: Our findings suggest that a brief course of ATG does not result in preservation of β-cell function 12 months later in patients with new-onset type 1 diabetes. Generalised T-cell depletion in the absence of specific depletion of effector memory T cells and preservation of regulatory T cells seems to be an ineffective treatment for type 1 diabetes. Funding: US National Institutes of Health and the Juvenile Diabetes Research Foundation.

Original languageEnglish (US)
Pages (from-to)306-316
Number of pages11
JournalThe Lancet Diabetes and Endocrinology
Issue number4
StatePublished - Dec 2013

Bibliographical note

Funding Information:
The trial was done by the Immune Tolerance Network (ITN) and sponsored by the National Institute of Allergy and Infectious Diseases (NIAID). Additional funding was provided by the Juvenile Diabetes Research Foundation (JDRF), the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a Clinical and Translational Awards grant (NIH/NCRR UCSF-CTSI Grant Number UL 1 TR000004 ), and Clinical and Translational Awards grants (UCSF-CTSI grant number UL1 RR024131 and UL 1 TR000004 ; CHOP by UL1RR024134 and UL1TR000003 ; University of Minnesota by UL1TR000114 ). Genzyme (Cambridge, MA, USA) provided ATG and gave input regarding dosage and safety, but had no direct involvement with study design, conduct, or management; data collection, analysis or interpretation; or manuscript preparation. There are no agreements concerning confidentiality of the data between the sponsor and the authors or the institutions named in the credit lines. The authors provided Genzyme a copy of the original paper before submission. Lifescan Inc (CA, USA) provided blood glucose monitoring meters and strips.


Dive into the research topics of 'Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial'. Together they form a unique fingerprint.

Cite this